COMMUNIQUÉS West-GlobeNewswire

EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of November 30, 2018
10/12/2018
Disclosure of Share Capital and Voting Rights Outstanding as of November 30, 2018 (Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité [...]
EssilorLuxottica : Nombre total de droits de vote et d'actions composant le capital social au 30 novembre 2018
10/12/2018
Nombre total de droits de vote et d'actions composant le capital social au 30 novembre 2018 (Conformément à l'article L.233-8 II du Code de Commerce et aux articles 221-1 et 223-16 du Règlement Général de l'AMF) [...]
Mereo BioPharma to Present at The BMO Prescriptions for Success Healthcare Conference on 12 December 2018
10/12/2018
Mereo BioPharma Group plc ("Mereo" or the "Company" or the "Group") LONDON, Dec. 10, 2018 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (AIM: MPH), a clinical stage, UK-based, biopharmaceutical company focused on rare [...]
Bio-on and Hera create Lux-on the new challenge to produce bioplastic from CO2.
10/12/2018
Newco Lux-on created by Bio-on, alongside Gruppo Hera, to develop a revolutionary technology to produce biopolymers from CO2 (carbon dioxide). Following 2 years of research by Bio-on scientists working in Italy and USA [...]
Bio-on et Hera insufflent la vie à Lux-on Toute dernière initiative pour produire des bioplastiques à base de CO2.
10/12/2018
On annonce la fondation de la société Lux-on, par Bio-on, avec la participation du groupe Hera, dont la mission est la mise au point d’une technologie révolutionnaire pour la production de bio-polymères à partir de CO 2 [...]
Basilea Pharmaceutica AG : Continued strong Cresemba® (isavuconazole) U.S. sales performance triggers CHF 10 million milestone payment to Basilea
10/12/2018
Basel, Switzerland, December 10, 2018 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the sales of the antifungal Cresemba ® (isavuconazole) by Astellas Pharma Inc. ("Astellas") in the United States [...]
Novartis data demonstrates consistent efficacy and tolerability of Kisqali® combination therapy in HR+/HER2- advanced breast cancer in patients with difficult-to-treat visceral disease
08/12/2018
Subgroup analyses of three pivotal Phase III MONALEESA trials showed Kisqali plus endocrine therapy extended PFS in all patients with and without visceral involvement compared to endocrine therapy alone; consistent with [...]
Arvinas Presents Preclinical Data on Protein Degrader, ARV-471, at the 2018 San Antonio Breast Cancer Symposium (SABCS)
08/12/2018
ARV-471 Degraded Estrogen Receptor and Provided Improved Anti-Tumor Activity When Compared to SOC, Both as a Monotherapy and in Combination NEW HAVEN, Conn., Dec. 07, 2018 (GLOBE NEWSWIRE) -- Arvinas Inc. (Nasdaq: ARVN [...]
Segra Postpones Go Public Strategy Citing Cannabis Market Conditions
08/12/2018
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ VANCOUVER, British Columbia, Dec. 07, 2018 (GLOBE NEWSWIRE) -- Segra International Corp., a cannabis agritech company, [...]
Abattis Announces Acquisition of Fertilizer Company NutriVida
08/12/2018
VANCOUVER, British Columbia, Dec. 07, 2018 (GLOBE NEWSWIRE) -- Abattis Bioceuticals Corp. (the “ Company ” or “ Abattis ”) (CSE:ATT) (OTC:ATTBF) is pleased to announce that it has signed a non-binding letter of intent [...]
Emerald Health Therapeutics Closes $10.8 Million Prospectus Sale
08/12/2018
VICTORIA, British Columbia, Dec. 07, 2018 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (TSXV:EMH; OTCQX:EMHTF) ("Emerald" or the “Company”) closed today its prospectus sale (the “Offering”) to a single Canadian [...]
Supreme Court of the State of Delaware Rules Against Akorn, New CEO Search Underway
07/12/2018
LAKE FOREST, Ill., Dec. 07, 2018 (GLOBE NEWSWIRE) -- Akorn, Inc. (NASDAQ: AKRX) today said it will move forward and rebuild shareholder value as an independent company following the disappointing decision from the [...]
Revive Announces a $2 Million Non-Brokered Private Placement
07/12/2018
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES TORONTO, Dec. 07, 2018 (GLOBE NEWSWIRE) -- Revive Therapeutics [...]
In Memoriam: Dr. Andreas Muhs CSO, Scientific Leader and Friend has Passed Away
07/12/2018
Lausanne, Switzerland, December 7, 2018 - AC Immune SA (NASDAQ: ACIU), announced today that its Chief Scientific Officer, Dr. Andreas Muhs, passed away following a period of illness. "It is with great sadness that we [...]
Indiana Minority Health Coalition in partnership with Side Effects Media and The Indianapolis Recorder will host two statewide town hall meetings!
07/12/2018
INDIANAPOLIS, Dec. 07, 2018 (GLOBE NEWSWIRE) -- On December 11, 2018, Indiana Minority Health Coalition in partnership with Side Effects Media and the Indianapolis Recorder will host two statewide virtual town hall [...]
MacroGenics Announces Partial Clinical Hold on MGD009 Phase 1 Studies
07/12/2018
ROCKVILLE, MD, Dec. 07, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for [...]
BIOPHYTIS Announces One Oral Presentation and Two Poster Presentations at the 11th International Conference on Cachexia, Sarcopenia and Muscle Wasting
07/12/2018
PARIS, Dec. 07, 2018 (GLOBE NEWSWIRE) -- BIOPHYTIS (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company developing first-in-class drug candidates for the treatment of age-related degenerative diseases [...]
ObsEva R&D Day Showcases Multiple Women’s Health Programs and Outlines Plans for Transition to Commercial Operations
07/12/2018
Clinical Trial Data and Regulatory Progress on Lead Programs Targeting IVF, Endometriosis, and Uterine Fibroids to Transform Company in 2019 GENEVA, Switzerland and BOSTON, Mass. (December 7, 2018) – ObsEva SA (NASDAQ: [...]
Affimed Announces U.S. Registrational Pathway and Updated Clinical Development Plan for AFM13 at R&D Day
07/12/2018
- Company to Pursue Registrational Pathway for Lead Agent AFM13 Monotherapy in Patients with Peripheral T Cell Lymphoma with Potential for Accelerated Approval - - Clinical Studies for AFM13 in Combination with anti-PD1 [...]

Pages